Sign in

NCT06462768Recruiting

Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis

Neutrophil Extracellular Traps in Systemic Sclerosis

Source: ClinicalTrials.gov · Last updated 17 Jun 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis. The loss of self-tolerance is believed to be caused by the dysregulation of both innate and adaptive immune systems and may involve Reactive Oxygen Species (ROS). Neutrophils are potent producers of ROS and may play a role in endothelial cells and fibrobasts dysfunction, as in autoantibodies generation. However, their role in SSC pathogenesis remains to be determined. Recent studies discovered abnormal regulation of Neutrophil Extracellular Traps (NETs) in other auto-immune diseases such as Systemic Lupus Erythematosus (SLE). NETs are web-like structures composed of chromatin backbones and granular molecules. They are released by activated neutrophils through a process called "NETosis". Nets were first described in 2004 as a novel host defense mechanism to trap and kill foreign pathogens. Recent evidence shows that NETs also participate in the pathogenesis of a variety of inflammatory and autoimmune diseases, including SLE. The investigators recently highlighted this phenomenon in SSc, especially in patients with vascular complications and/or at a early stage of the disease. The investigators will now explore the factors implicated in this dysregulation of NETosis in SSc.

Status (registry)
Recruiting
Study type
Observational
Enrollment
260 (estimated)
First submitted
12 Jun 2024
Start date
27 Nov 2023
Primary completion date
27 Oct 2028
Lead sponsor
CHU de Reims
NCT number
NCT06462768

What you commit to

  • Study type: Observational
  • Planned participants: 260
  • From 27 Nov 2023 to the primary completion date, 27 Oct 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion

Age

  • Patients/Healthy volunteers under 18 years old

Other

  • Patients/Healthy volunteers protected by the law
  • Patients/Healthy volunteers not consenting to participate to the study after information
  • Pregnant or breastfeeding women

Who the study is looking for

  • \*For patients of group 1:
  • Patients with systemic sclerosis (ACR-EULAR Criteria)
  • Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
  • Patients consenting to participate to the study
  • Patients enrolled in the national healthcare insurance program
    • For patients of group 2:
  • Patients with other connective tissue disease (ACR specific-disease criteria)
  • Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims
  • Patients consenting to participate to the study
  • Patients enrolled in the national healthcare insurance program
    • For patients of group 3 (healthy volunteers)
  • Patients eligible for blood donation (blood donation regulation criteria of January 11th 2022 decree)
  • Patients without medical history of autoimmune systemic or chronic inflammatory systemic disease,
  • Patients without current or past neoplasy disease,
  • Patients without chronic metabolic pathology
  • Patients without treatment by anti inflammatory or corticotherapy for the last 15 days,
  • Patients without infectious pathology or inflammatory acute for the last 15 days
  • Patients consenting to participate to the study

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
CHU Reims
Coordinator of this site? Confirm its status
ReimsFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.